Holen Sie sich die Stockscreener-App
921.03
1.61%
-14.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$935.58
Offen:
$932.04
24-Stunden-Volumen:
952.43K
Relative Volume:
0.31
Marktkapitalisierung:
$822.79B
Einnahmen:
$65.18B
Nettoeinkommen (Verlust:
$20.64B
KGV:
40.77
EPS:
22.5894
Netto-Cashflow:
$5.96B
1W Leistung:
+3.82%
1M Leistung:
-7.05%
6M Leistung:
+8.93%
1J Leistung:
+24.70%
1-Tages-Spanne:
$920.32
$936.00
1-Wochen-Bereich:
$892.14
$976.68
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
921.01 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.88 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
205.40 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.58 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.32 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly takes the court with 150th anniversary campaign to catch Final Four crowd - Fierce Pharma
Eli Lilly & Co. stock: Foundayo approval drives gains – what it means for you - AD HOC NEWS
Eli Lilly's $6.5B Houston plant will make its new FDA-approved GLP-1 weight loss drug - The Business Journals
Evexia Wealth LLC Sells 1,147 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY is Aberdeen Group plc's 10th Largest Position - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Rating Lowered by Wall Street Zen - MarketBeat
Eli Lilly's Foundayo Launch and Strategic Acquisition Signal Aggressive Growth - AD HOC NEWS
StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod - Genetic Engineering and Biotechnology News
Oral Weight-Loss Drug Battle: Novo Nordisk vs Eli Lilly's New TreatmentsNews and Statistics - indexbox.io
AI Models Split on Eli Lilly (LLY) as Growth Strength Meets Premium Valuation - TipRanks
HF Advisory Group LLC Boosts Stake in Eli Lilly and Company $LLY - MarketBeat
Herbst Group LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Banque Pictet & Cie SA Cuts Holdings in Eli Lilly and Company $LLY - MarketBeat
Beacon Investment Advisory Services Inc. Sells 1,080 Shares of Eli Lilly and Company $LLY - MarketBeat
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” - Insider Monkey
Eli Lilly (LLY) Is Up 6.5% After FDA Clears Anytime Oral GLP-1 Foundayo for Obesity Treatment - simplywall.st
Jim Cramer Likes Eli Lilly’s (LLY) New Deal - Insider Monkey
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool
Eli Lilly and Company $LLY Shares Sold by Weatherly Asset Management L. P. - MarketBeat
Frank Rimerman Advisors Boosts Eli Lilly Stock Position - National Today
Mounjaro: Eli Lilly's GLP-1 Powerhouse Driving Weight Loss Revolution and Investor Interest in North - AD HOC NEWS
Eli Lilly and Company $LLY is Tema Etfs LLC's 4th Largest Position - MarketBeat
Elser Financial Planning Boosts Stake in Eli Lilly - National Today
Elser Financial Planning Inc Has $28.18 Million Stake in Eli Lilly and Company $LLY - MarketBeat
How Eli Lilly’s oral GLP-1 could change the obesity drug market - Healthcare Brew
Eli Lilly (LLY) Valuation Check As Foundayo Oral GLP 1 Approval Lifts Obesity Growth Story - simplywall.st
Eli Lilly’s new GLP-1 weight loss pill Foundayo receives FDA approval - inkfreenews.com
Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill - Insider Monkey
Insilico and Eli Lilly Announce a Major Collaboration - Lifespan Research Institute
Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors - TipRanks
Eli Lilly and Company stock: Foundayo approval ignites 2026 boom? - AD HOC NEWS
To celebrate its anniversary, Eli Lilly marks 150 years of everything else - PRWeek
Should You Be Adding Eli Lilly (NYSE:LLY) To Your Watchlist Today? - 富途牛牛
Novo Nordisk Weight Loss Pill Outperforms Eli Lilly Rival in New Clinical Trial Data - TIKR.com
Nisa Investment Advisors Boosts Stake in Eli Lilly - National Today
Nisa Investment Advisors LLC Raises Holdings in Eli Lilly and Company $LLY - MarketBeat
Moody Lynn & Lieberson LLC Purchases 2,657 Shares of Eli Lilly and Company $LLY - MarketBeat
Nikulski Financial Inc. Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (LLY) expands Zepbound access as pricing reforms boost long-term growth outlook - MSN
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions - Manufacturing Chemist
Eli Lilly Stock (LLY) Opinions on FDA Approval of Foundayo - Moomoo
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion - thelec.net
FDA approves Eli Lilly's new weight loss pill with no food restrictions - qz.com
Eli Lilly's Foundayo Pill Approved: Stock Gains, Launch April 6, 2026News and Statistics - IndexBox
Eli Lilly, Novo Nordisk Intensify Competition With Oral Obesity Drugs - thelec.net
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why - Yahoo Finance Singapore
Eli Lilly and Company (NYSE:LLY) Shares Down 2%Should You Sell? - MarketBeat
Novo Nordisk: Competing In A Duopoly (TSX:NOVO:CA) - Seeking Alpha
A new weight-loss pill is here, and it could reshape the GLP-1 market - Fast Company
Stocks with rising composite ratings: Eli Lilly - MSN
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):